Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 29;10(11):ofad474.
doi: 10.1093/ofid/ofad474. eCollection 2023 Nov.

Effectiveness of the Original Monovalent Coronavirus Disease 2019 Vaccines in Preventing Emergency Department or Urgent Care Encounters and Hospitalizations Among Adults With Disabilities: VISION Network, June 2021-September 2022

Palak Patel  1 , Kristin E Schrader  2 , Catherine E Rice  3 , Elizabeth Rowley  2 , Robyn A Cree  3 , Malini B DeSilva  4 , Peter J Embi  5 , Manjusha Gaglani  6   7 , Shaun J Grannis  8   9 , Toan C Ong  10 , Edward Stenehjem  11 , Allison L Naleway  12 , Sarah Ball  2 , Karthik Natarajan  13   14 , Nicola P Klein  15 , Katherine Adams  1 , Anupam Kharbanda  16 , Caitlin Ray  1 , Ruth Link-Gelles  17 , Mark W Tenforde  1
Affiliations

Effectiveness of the Original Monovalent Coronavirus Disease 2019 Vaccines in Preventing Emergency Department or Urgent Care Encounters and Hospitalizations Among Adults With Disabilities: VISION Network, June 2021-September 2022

Palak Patel et al. Open Forum Infect Dis. .

Abstract

Adults with disabilities are at increased risk for severe coronavirus disease 2019 (COVID-19). Using data across 9 states during Delta- and Omicron-predominant periods (June 2021-September 2022), we evaluated the effectiveness of the original monovalent COVID-19 messenger RNA vaccines among 521 206 emergency department/urgent care encounters (11 471 [2%] in patients with a documented disability) and 139 548 hospitalizations (16 569 [12%] in patients with a disability) for laboratory-confirmed COVID-19 illness in adults (aged ≥18 years). Across variant periods and for the primary series or booster doses, vaccine effectiveness was similar in those with and those without a disability. These findings highlight the importance of adults with disabilities staying up to date with COVID-19 vaccinations.

Keywords: COVID-19; disabilities; test-negative design; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. A. L. N. reports institutional support from Pfizer for an unrelated study of meningococcal B vaccine safety during pregnancy. N. P. K. reports institutional support from Pfizer, Merck, GlaxoSmithKline (GSK), Sanofi Pasteur, and Protein Sciences (now Sanofi Pasteur) for unrelated studies and institutional support from Pfizer for coronavirus disease 2019 vaccine clinical trials. All other authors report no potential conflicts.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) against laboratory-confirmed COVID-19–associated emergency department and urgent care (ED/UC) encounters and hospitalizations among adults aged ≥18 years with or without a disability (VISION Network, June 2021 to September 2022). VE was estimated as (1 – adjusted odds ratio) × 100%, using multivariable logistic regression with inverse-propensity-to-be-vaccinated weights and adjusting for site, calendar time (days since 1 January 2021), age, local virus circulation (percentage of positive severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] test results from testing within the counties surrounding the facility on the date of the encounter), and any variable not considered balanced after the propensity score (ie, with standardized mean difference >0.2. Dashes (missing values) indicate that the estimated VE had a confidence interval (CI) width ≥50%. Estimates with CI widths ≥50% are not shown here because of imprecision, and the associated data are also omitted. Abbreviations: IQR, interquartile range; mRNA, messenger RNA; NA, not applicable; Ref, referent group.
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention (CDC). Disability inclusion: disability and health promotion. Available at: https://www.cdc.gov/ncbddd/disabilityandhealth/disability-inclusion.html. Accessed 31 October 2023.
    1. Centers for Disease Control and Prevention (CDC). Disability and health overview: impairments, activity limitations, and participation restrictions. Available at: https://www.cdc.gov/ncbddd/disabilityandhealth/disability.html. Accessed 31 October 2023.
    1. Centers for Disease Control and Prevention (CDC). COVID-19. People with certain medical conditions. Available at: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-.... Accessed 31 October 2023.
    1. Clarke KEN, Hong K, Schoonveld M, Greenspan AI, Montgomery M, Thierry JM. Severity of coronavirus disease 2019 hospitalization outcomes and patient disposition differ by disability status and disability type. Clin Infect Dis 2022; 76:871–80. - PMC - PubMed
    1. Clift AK, Coupland CA, Keogh RH, Hemingway H, Hippisley-Cox J. COVID-19 mortality risk in Down syndrome: results from a cohort study of 8 million adults. Ann Intern Med 2021; 174:572–6. - PMC - PubMed